Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
BeOne Medicines
BeOne Medicines
Dragonfly Therapeutics
NeoImmuneTech
University Health Network, Toronto
Akeso
Medical University of South Carolina
Incyte Corporation
Amgen
Big Ten Cancer Research Consortium
Big Ten Cancer Research Consortium
Lumicell, Inc.
Exelixis
Jacobio Pharmaceuticals Co., Ltd.
Bristol-Myers Squibb
Hoffmann-La Roche
Shanghai Junshi Bioscience Co., Ltd.
Massachusetts General Hospital
CRISPR Therapeutics
NantCell, Inc.
M.D. Anderson Cancer Center
Ipsen
Dragonfly Therapeutics
G1 Therapeutics, Inc.
Shanghai Escugen Biotechnology Co., Ltd
Mayo Clinic
Incyte Corporation
Palleon Pharmaceuticals, Inc.
Incyte Corporation
Incyte Corporation
Genfleet Therapeutics (Shanghai) Inc.
CellCentric Ltd.
Royal Marsden NHS Foundation Trust
Navigation Sciences, Inc.
National Institutes of Health Clinical Center (CC)
PharmaMar
City of Hope Medical Center
Jiangsu HengRui Medicine Co., Ltd.
TransThera Sciences (Nanjing), Inc.
Blanco, Dr Antonio Calles MD
Hoffmann-La Roche
NGM Biopharmaceuticals, Inc
Immuneering Corporation
Mural Oncology, Inc
Memorial Sloan Kettering Cancer Center
Aprea Therapeutics
National Institutes of Health Clinical Center (CC)
Gustave Roussy, Cancer Campus, Grand Paris
University Hospital, Antwerp
Janssen Research & Development, LLC
National Institutes of Health Clinical Center (CC)